Page last updated: 2024-12-06

sch 34343

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72445
CHEMBL ID306713
SCHEMBL ID10396007
MeSH IDM0130205

Synonyms (16)

Synonym
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((2-((aminocarbonyl)oxy)ethyl)thio)-6-(1-hydroxyethyl)-7-oxo-, monosodium salt, (5r-(5alpha,6alpha))-
sch34343
sch 34343
(5r,6s)-3-(2-carbamoyloxyethylsulfanyl)-6-[(1r)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
95415-91-1
sch-34343
CHEMBL306713
2-carbamoyloxyethylthio-6-(1-hydroxyethyl)penem-3-carboxylic acid
wm2tr07vx3 ,
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((2-((aminocarbonyl)oxy)ethyl)thio)-6-(1-hydroxyethyl)-7-oxo-, (5r-(5alpha,6alpha))-
unii-wm2tr07vx3
SCHEMBL10396007
DTXSID60873378
(5r,6s)-3-((2-((aminocarbonyl)oxy)ethyl)thio)-6-((1r)-1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((2-((aminocarbonyl)oxy)ethyl)thio)-6-((1r)-1-hydroxyethyl)-7-oxo-, (5r,6s)-
sch-34343 free acid

Research Excerpts

Overview

Sch 34343 is a new penem antibiotic. It can penetrate into anaerobic abscesses and can kill large numbers of bacteria.

ExcerptReferenceRelevance
"Sch 34343 is a new penem antibiotic. "( In-vitro activity and beta-lactamase stability and inhibitory properties of a new penem antibiotic, Sch 34343.
Chin, NX; Labthavikul, P; Neu, HC, 1985
)
1.93
"Sch 34343 is a promising agent for the treatment of anaerobic infections because it can penetrate into anaerobic abscesses and can kill large numbers of bacteria within abscesses."( In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
Arland, LA; Rotstein, OD; Simmons, RL; Wells, CL, 1985
)
1.27

Actions

Sch 34343 did not inhibit Pseudomonas spp., and it had slightly less activity against Enterobacteriaceae than did cefotaxime or latamoxef (moxalactam) It inhibited organisms resistant to cefoxitin, cefoperazone and piperacillin.

ExcerptReferenceRelevance
"Sch 34343 did not inhibit Pseudomonas spp., and it had slightly less activity against Enterobacteriaceae than did cefotaxime or latamoxef (moxalactam), but it inhibited organisms resistant to cefoxitin, cefoperazone and piperacillin."( In-vitro activity and beta-lactamase stability and inhibitory properties of a new penem antibiotic, Sch 34343.
Chin, NX; Labthavikul, P; Neu, HC, 1985
)
1.21
"Sch 34343 did not inhibit Pseudomonas aeruginosa."( Sch 34343, in-vitro antibacterial activity and beta-lactamase stability.
Houben, AW; Stobberingh, EE; van Boven, CP, 1985
)
2.43

Pharmacokinetics

ExcerptReferenceRelevance
" Following both routes of drug administration, the elimination of half-life (T 1/2 beta) was 7 min in rats and 25-32 min in dogs."( Pharmacokinetics of Sch 34343 in rats and dogs.
Chung, M; D'Souza, R; Kim, H; Korduba, C; Lim, J; Lin, C; Loebenberg, D; Moss, E; Oden, E; Veals, J, 1985
)
0.59
" The pertinent pharmacokinetic parameters tested are apparent and steady-state volumes of distribution, total body clearance, elimination phase half-life, and mean residence time."( Interspecies pharmacokinetic scaling of Sch 34343.
Chung, M; Gural, RP; Lin, CC; Loebenberg, D; Miller, GH; Oden, E; Radwanski, E; Symchowicz, S, 1985
)
0.54
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" The serum AUC for total radioactivity and for intact drug after intramuscular dosing were similar to those obtained after intravenous dosing."( Pharmacokinetics of Sch 34343 in rats and dogs.
Chung, M; D'Souza, R; Kim, H; Korduba, C; Lim, J; Lin, C; Loebenberg, D; Moss, E; Oden, E; Veals, J, 1985
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1354444Antimicrobial activity against Yersinia pestis KIM6+2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1354443Antimicrobial activity against Staphylococcus epidermidis RP26A2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1354446Antimicrobial activity against Yersinia pestis KIM6+ harboring arabinose inducible type 1 signal peptidase in presence of 2% arabinose2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID1354441Inhibition of Escherichia coli type 1 signal peptidase using peptide substrate after 30 mins by fluorescence assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (90.57)18.7374
1990's1 (1.89)18.2507
2000's3 (5.66)29.6817
2010's1 (1.89)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.50 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]